Zymeworks Inc. (ZYME)
USD 12.96
(0.62%)
USD 12.96
(0.62%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -118.67 Million USD | -195.44% |
| 2022 | 124.34 Million USD | 158.69% |
| 2021 | -211.84 Million CAD | -17.33% |
| 2020 | -180.55 Million USD | -24.14% |
| 2019 | -145.43 Million USD | -297.85% |
| 2018 | -36.55 Million USD | -251.3% |
| 2017 | -10.4 Million USD | 69.22% |
| 2016 | -33.8 Million USD | -76.36% |
| 2015 | -19.17 Million USD | -48.12% |
| 2014 | -12.94 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -37.68 Million USD | -19.06% |
| 2024 Q1 | -31.65 Million USD | -118.57% |
| 2024 Q3 | -29.85 Billion USD | 20.79% |
| 2023 Q3 | -28.68 Million USD | 43.92% |
| 2023 Q1 | -24.35 Million USD | -107.87% |
| 2023 Q2 | -51.15 Million USD | -110.04% |
| 2023 FY | -118.67 Million USD | -195.44% |
| 2023 Q4 | -14.48 Million USD | 49.52% |
| 2022 Q2 | -64.61 Million USD | 11.02% |
| 2022 FY | 124.34 Million USD | 158.69% |
| 2022 Q4 | 309.43 Million USD | 746.72% |
| 2022 Q3 | -47.84 Million USD | 25.96% |
| 2022 Q1 | -72.62 Million USD | -85.49% |
| 2021 Q4 | -39.15 Million CAD | 35.37% |
| 2021 Q2 | -67.52 Million USD | -51.43% |
| 2021 FY | -211.84 Million CAD | -17.33% |
| 2021 Q1 | -44.59 Million USD | -17.67% |
| 2021 Q3 | -60.57 Million USD | 10.28% |
| 2020 Q2 | -38.96 Million USD | -25.13% |
| 2020 Q1 | -31.13 Million USD | 56.9% |
| 2020 Q4 | -37.89 Million USD | 47.78% |
| 2020 FY | -180.55 Million USD | -24.14% |
| 2020 Q3 | -72.56 Million USD | -86.24% |
| 2019 Q1 | -13.64 Million USD | -247.1% |
| 2019 FY | -145.43 Million USD | -297.85% |
| 2019 Q4 | -72.24 Million USD | -137.06% |
| 2019 Q3 | -30.47 Million USD | -4.81% |
| 2019 Q2 | -29.07 Million USD | -113.16% |
| 2018 Q3 | -18.75 Million USD | -219.22% |
| 2018 Q4 | 9.27 Million USD | 149.45% |
| 2018 FY | -36.55 Million USD | -251.3% |
| 2018 Q1 | -21.2 Million USD | -164.78% |
| 2018 Q2 | -5.87 Million USD | 72.3% |
| 2017 Q1 | -15.92 Million USD | -41.23% |
| 2017 Q2 | -10.96 Million USD | 31.13% |
| 2017 Q3 | -16.24 Million USD | -48.11% |
| 2017 Q4 | 32.73 Million USD | 301.5% |
| 2017 FY | -10.4 Million USD | 69.22% |
| 2016 Q3 | -12.39 Million USD | -67.01% |
| 2016 Q2 | -7.42 Million USD | -173.71% |
| 2016 Q1 | -2.71 Million USD | 65.78% |
| 2016 FY | -33.8 Million USD | -76.36% |
| 2016 Q4 | -11.27 Million USD | 9.03% |
| 2015 FY | -19.17 Million USD | -48.12% |
| 2015 Q4 | -7.92 Million USD | 0.0% |
| 2014 FY | -12.94 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ADC Therapeutics SA | -240.05 Million USD | 50.563% |
| Alto Neuroscience, Inc. | -36.3 Million USD | -226.881% |
| Annovis Bio, Inc. | -56.2 Million USD | -111.147% |
| Biohaven Pharmaceutical Holding Company Ltd. | -408.16 Million USD | 70.925% |
| Ginkgo Bioworks Holdings, Inc. | -892.86 Million USD | 86.709% |
| Nuvation Bio Inc. | -75.8 Million USD | -56.558% |
| Nuvation Bio Inc. | -75.8 Million USD | -56.558% |
| Arcus Biosciences, Inc. | -307 Million USD | 61.344% |